⌕
Bristol-Myers Squibb · BMY · NYSE
Tenet 51 · Mixed
Compare
$62.93−0.79%At closeTenet 51 · Mixed
$62.93−0.50 (−0.79%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$63.10+0.17 (+0.27%)
After hours: Nov 16, 2026, 6:51 PM ET

Bristol-Myers Squibb (BMY) Stock

Bristol-Myers Squibb (BMY) closed at $62.93 on Nov 16, 2026; its Tenet Score is 51 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$62.93
Nov 16, 2026
Market cap
$129.7B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
14.0×
price ÷ earnings
Dividend yield
3.97%
past year's regular dividends ÷ price
52-week range
45.27 – 68.64
low → high · as of close, Nov 13, 2026
Tenet Score
51/100
Mixed · 313 Healthcare peers

Industry: Drugs

Bristol-Myers Squibb Co. scores 51/100. Mixed. Strongest on value and quality, financial health is the soft spot, trading at 14× earnings versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
51/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
74
Quality
65
Health
25
Growth
41

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityCHealthFGrowthDMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
5.5×
price to book value
P/S
2.6×
price to fiscal 2025 sales
ROE
44%
return on equity
Operating margin
20.8%
fiscal 2025, before interest and tax
Net margin
18.5%
of revenue kept
Current ratio
1.59
current assets to liabilities
Net debt / EBITDA
2.1×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 468 US ETFs · top wrappers by weightSee all ETFs holding BMY →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

CompanyTenet ScoreMarket cap
AMGEN Inc.AMGN47$251.9B
Gilead Sciences, Inc.GILD37$208.5B
Novo NordiskNVO63$185.9B
Pfizer Inc.PFE50$164.7B
Vertex Pharmaceuticals, Inc.VRTX55$136.6B
GSK PlcGSK51$108.9B
Regeneron Pharmaceuticals, Inc.REGN64$98.8B
Moderna IncMRNA33$90.4B
Takeda Pharmaceutical CoTAK32$73.9B
Argen X SEARGX71$59.4B

Compare Bristol-Myers Squibb with

What sector and industry is Bristol-Myers Squibb in?

Bristol-Myers Squibb is in the Healthcare sector and the Drugs industry.

What is Bristol-Myers Squibb's Tenet Score?

Bristol-Myers Squibb's Tenet Score is 51 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.